LM 3370
Latest Information Update: 06 Jun 2001
Price :
$50 *
At a glance
- Originator Merck Sante
- Class Piperazines
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Septic shock
Most Recent Events
- 06 Jun 2001 Discontinued-Preclinical for Septic shock in France (Unknown route)
- 03 Aug 1998 No-Development-Reported for Septic shock in France (Unknown route)
- 09 Oct 1995 Preclinical development for Septic shock in France (Unknown route)